scholarly journals The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease

10.1186/rr18 ◽  
2000 ◽  
Vol 1 (2) ◽  
Author(s):  
Jean-Michel Sallenave
2010 ◽  
Vol 9 (3) ◽  
pp. 197-205 ◽  
Author(s):  
Abbas Imanifooladi ◽  
Samaneh Yazdani ◽  
Mohammad Nourani

2013 ◽  
pp. 81-98 ◽  
Author(s):  
Victor Kim ◽  
Kosuke Kato ◽  
K. Chul Kim ◽  
Erik P. Lillehoj

1998 ◽  
Vol 42 (11) ◽  
pp. 2973-2977 ◽  
Author(s):  
Mathirut Mungthin ◽  
Patrick G. Bray ◽  
Robert G. Ridley ◽  
Stephen A. Ward

ABSTRACT We have used a specific inhibitor of the malarial aspartic proteinase plasmepsin I and a nonspecific cysteine proteinase inhibitor to investigate the importance of hemoglobin degradation in the mechanism of action of chloroquine, amodiaquine, quinine, mefloquine (MQ), halofantrine, and primaquine. Both proteinase inhibitors antagonized the antiparasitic activity of all drugs tested with the exception of primaquine. An inhibitor of plasmepsin I, Ro40-4388, reduced the incorporation of radiolabelled chloroquine and quinine into malarial pigment by 95%, while causing a 70% reduction in the incorporation of radiolabelled MQ. Cysteine proteinase inhibitor E64 reduced the incorporation of chloroquine and quinine into malarial pigment by 60 and 40%, respectively. This study provides definitive support for the central role of hemoglobin degradation in the mechanism of action of the 4-aminoquinolines and the quinoline and phenanthrene methanol antimalarials.


2020 ◽  
Vol 34 (10) ◽  
pp. 13156-13170
Author(s):  
Ruihua Ma ◽  
Tatiana P. Ortiz Serrano ◽  
Jennifer Davis ◽  
Andrew D. Prigge ◽  
Karen M. Ridge

1984 ◽  
Vol 55 ◽  
pp. 297-306 ◽  
Author(s):  
J E Gadek ◽  
G A Fells ◽  
R L Zimmerman ◽  
R G Crystal

2001 ◽  
Vol 90 (6) ◽  
pp. 2311-2318 ◽  
Author(s):  
Monica J. Marantz ◽  
Sandra G. Vincent ◽  
John T. Fisher

We addressed the hypothesis that vagal C-fiber afferents and cyclooxygenase products are the mechanisms responsible for lactic acid (LA)-induced bronchoconstriction in the newborn dog. Perineural capsaicin and indomethacin were used to block conduction of vagal C fibers and production of cyclooxygenase products, respectively. Perineural capsaicin eliminated (85%) the increase in lung resistance (Rl; 45 ± 5.6%) due to capsaicin (25 μg/kg), whereas the increase in Rl (54 ± 6.9%) due to LA (0.4 mmol/kg) was only inhibited by 37 ± 4.7% ( P < 0.05). Atropine reduced LA-induced bronchoconstriction (42 ± 2.1%) by an amount similar to that obtained with perineural capsaicin. However, inhibition was significantly increased when atropine was combined with indomethacin (61 ± 2.7%; P < 0.05), implicating cyclooxygenase products in the LA-induced bronchoconstrictor response. We conclude that the mechanisms responsible for LA-induced bronchoconstriction in the newborn are 1) activation of vagal C-fibers, which, through projections to medullary respiratory centers, leads to activation of vagal cholinergic efferents; 2) production of cyclooxygenase products, which cause bronchoconstriction independent of medullary involvement; and 3) an unknown bronchoconstrictor mechanism, putatively tachykinin mediated. On the basis of our data, pharmaceutical targeting of pulmonary afferents would prevent multiple downstream mechanisms that lead to airway narrowing due to inflammatory lung disease.


Sign in / Sign up

Export Citation Format

Share Document